| Endpoint . | AE stratum . | Duloxetine . | Placebo . | Difference (95% CI for difference) . |
|---|---|---|---|---|
| Patient perception of benefit (%) | Never | 68.2 | 41.3 | 26.9 (7.7 to 44.8)b |
| Duloxetine | 73.3 | 41.8 | 31.5 (15.4 to 47.2)b | |
| Always | 72.0 | 57.7 | 14.3 (-0.5 to 29.0) | |
| Change in functional quality of life (FACT-ES TOI) | Never | 10.2 | 10.3 | -0.1 (-5.4 to 5.0) |
| Duloxetine | 11.3 | 9.0 | 2.3 (-2.2 to 6.8) | |
| Always | 12.3 | 12.3 | 0.0 (-4.0 to 4.0) |
| Endpoint . | AE stratum . | Duloxetine . | Placebo . | Difference (95% CI for difference) . |
|---|---|---|---|---|
| Patient perception of benefit (%) | Never | 68.2 | 41.3 | 26.9 (7.7 to 44.8)b |
| Duloxetine | 73.3 | 41.8 | 31.5 (15.4 to 47.2)b | |
| Always | 72.0 | 57.7 | 14.3 (-0.5 to 29.0) | |
| Change in functional quality of life (FACT-ES TOI) | Never | 10.2 | 10.3 | -0.1 (-5.4 to 5.0) |
| Duloxetine | 11.3 | 9.0 | 2.3 (-2.2 to 6.8) | |
| Always | 12.3 | 12.3 | 0.0 (-4.0 to 4.0) |
Principal stratum treatment effects reported as per-arm posterior means and comparison-wise 95% credible intervals (CIs). Treatment effect on perceived benefit (percentage point difference), and treatment effect on functional quality of life (FACT-ES TOI score difference). FACT-ES TOI = Functional Assessment of Cancer Therapy-Endocrine Scale trial outcome index.
Credible intervals adjusted for multiplicity of principal strata do not contain zero.
| Endpoint . | AE stratum . | Duloxetine . | Placebo . | Difference (95% CI for difference) . |
|---|---|---|---|---|
| Patient perception of benefit (%) | Never | 68.2 | 41.3 | 26.9 (7.7 to 44.8)b |
| Duloxetine | 73.3 | 41.8 | 31.5 (15.4 to 47.2)b | |
| Always | 72.0 | 57.7 | 14.3 (-0.5 to 29.0) | |
| Change in functional quality of life (FACT-ES TOI) | Never | 10.2 | 10.3 | -0.1 (-5.4 to 5.0) |
| Duloxetine | 11.3 | 9.0 | 2.3 (-2.2 to 6.8) | |
| Always | 12.3 | 12.3 | 0.0 (-4.0 to 4.0) |
| Endpoint . | AE stratum . | Duloxetine . | Placebo . | Difference (95% CI for difference) . |
|---|---|---|---|---|
| Patient perception of benefit (%) | Never | 68.2 | 41.3 | 26.9 (7.7 to 44.8)b |
| Duloxetine | 73.3 | 41.8 | 31.5 (15.4 to 47.2)b | |
| Always | 72.0 | 57.7 | 14.3 (-0.5 to 29.0) | |
| Change in functional quality of life (FACT-ES TOI) | Never | 10.2 | 10.3 | -0.1 (-5.4 to 5.0) |
| Duloxetine | 11.3 | 9.0 | 2.3 (-2.2 to 6.8) | |
| Always | 12.3 | 12.3 | 0.0 (-4.0 to 4.0) |
Principal stratum treatment effects reported as per-arm posterior means and comparison-wise 95% credible intervals (CIs). Treatment effect on perceived benefit (percentage point difference), and treatment effect on functional quality of life (FACT-ES TOI score difference). FACT-ES TOI = Functional Assessment of Cancer Therapy-Endocrine Scale trial outcome index.
Credible intervals adjusted for multiplicity of principal strata do not contain zero.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
